Total Payments
$11,982
2024 Payments
$848.89
Companies
57
Transactions
802
Medicare Patients
10,894
Medicare Billing
$6.0M
Payment Breakdown by Category
Food & Beverage$11,718 (97.8%)
Education$264.97 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,718 | 791 | 97.8% |
| Education | $264.97 | 11 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,107 | 107 | $0 (2024) |
| ABBVIE INC. | $874.26 | 56 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $745.36 | 40 | $0 (2023) |
| PFIZER INC. | $656.04 | 61 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $587.74 | 46 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $585.21 | 34 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $566.43 | 46 | $0 (2020) |
| Merck Sharp & Dohme LLC | $553.38 | 31 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $531.15 | 26 | $0 (2024) |
| GlaxoSmithKline, LLC. | $521.42 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $848.89 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($101.95) |
| 2023 | $1,787 | 99 | Otsuka America Pharmaceutical, Inc. ($256.10) |
| 2022 | $1,539 | 84 | Bayer HealthCare Pharmaceuticals Inc. ($166.56) |
| 2021 | $1,694 | 99 | AbbVie Inc. ($415.74) |
| 2020 | $749.25 | 40 | Allergan, Inc. ($125.49) |
| 2019 | $1,597 | 133 | AstraZeneca Pharmaceuticals LP ($215.97) |
| 2018 | $2,064 | 162 | Novo Nordisk Inc ($338.09) |
| 2017 | $1,704 | 143 | PFIZER INC. ($215.86) |
All Payment Transactions
802 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | VIVUS LLC | QSYMIA (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: PSYCHIATRY | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: ANTI-ANXIETY | ||||||
| 11/04/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Endocrinology | ||||||
| 10/23/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Inflammation | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: RESPIRATORY | ||||||
| 10/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Cardio-renal | ||||||
| 10/21/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Neurology | ||||||
| 10/15/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: PAIN | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: DIABETES | ||||||
| 09/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Diabetes | ||||||
| 09/08/2024 | Almatica Pharma LLC | TERIPARATIDE (Drug), LOREEV XR | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: OSTEOPOROSIS | ||||||
| 08/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Biological | ||||||
| 08/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Cardio-renal | ||||||
| 08/16/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $30.87 | General |
| Category: Biological | ||||||
| 07/31/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/29/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: NEUROSCIENCE | ||||||
| 07/17/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Diabetes | ||||||
| 07/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: DIABETES | ||||||
| 06/21/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 3,135 | 17,380 | $8.1M | $2.1M |
| 2022 | 30 | 2,362 | 13,640 | $6.2M | $1.5M |
| 2021 | 30 | 2,343 | 11,387 | $3.7M | $1.2M |
| 2020 | 32 | 3,054 | 11,684 | $3.5M | $1.2M |
Total Patients
10,894
Total Services
54,091
Medicare Billing
$6.0M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 255 | 5,384 | $2.2M | $811,730 | 37.7% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 250 | 5,409 | $2.7M | $668,941 | 24.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 405 | 2,479 | $1.2M | $238,987 | 19.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 83 | 503 | $603,600 | $86,596 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 279 | 767 | $172,575 | $73,610 | 42.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 336 | 409 | $409,000 | $56,768 | 13.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 393 | 483 | $289,800 | $44,963 | 15.5% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 197 | 227 | $181,600 | $33,249 | 18.3% |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 2023 | 244 | 494 | $123,500 | $23,527 | 19.1% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 63 | 172 | $34,400 | $14,658 | 42.6% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2023 | 98 | 113 | $67,800 | $12,057 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 74 | 74 | $25,900 | $10,422 | 40.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 78 | 78 | $15,600 | $10,269 | 65.8% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 25 | 103 | $36,050 | $10,052 | 27.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 20 | 20 | $9,720 | $4,370 | 45.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 76 | 91 | $18,200 | $3,851 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 37 | $9,250 | $3,375 | 36.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 77 | $13,475 | $3,253 | 24.1% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 16 | 16 | $3,200 | $2,722 | 85.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 107 | $6,420 | $1,136 | 17.7% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 22 | 22 | $1,760 | $736.78 | 41.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $1,320 | $701.36 | 53.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 50 | 63 | $1,575 | $529.20 | 33.6% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 11 | 12 | $1,800 | $394.50 | 21.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 23 | 24 | $2,400 | $275.77 | 11.5% |
About Dr. Andro Sharobiem, M.D
Dr. Andro Sharobiem, M.D is a Internal Medicine healthcare provider based in Riverside, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1073711453.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andro Sharobiem, M.D has received a total of $11,982 in payments from pharmaceutical and medical device companies, with $848.89 received in 2024. These payments were reported across 802 transactions from 57 companies. The most common payment nature is "Food and Beverage" ($11,718).
As a Medicare-enrolled provider, Sharobiem has provided services to 10,894 Medicare beneficiaries, totaling 54,091 services with total Medicare billing of $6.0M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Riverside, CA
- Active Since 07/06/2007
- Last Updated 07/02/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1073711453
Products in Payments
- XIFAXAN (Drug) $616.40
- ELIQUIS (Drug) $613.34
- REXULTI (Drug) $506.61
- FARXIGA (Drug) $369.62
- UBRELVY (Drug) $359.62
- Kerendia (Drug) $351.07
- JARDIANCE (Drug) $350.42
- NURTEC ODT (Drug) $324.74
- VRAYLAR (Drug) $300.40
- Ozempic (Drug) $294.85
- Briviact (Drug) $289.11
- LONHALA MAGNAIR (Drug) $284.43
- Rybelsus (Drug) $277.06
- XARELTO (Drug) $254.09
- ENTRESTO (Drug) $239.97
- Tymlos (Biological) $233.37
- APTIOM (Drug) $224.71
- BELSOMRA (Drug) $205.89
- SYMBICORT (Drug) $204.85
- LINZESS (Drug) $200.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Riverside
Dr. Christopher Swanson, M.d, M.D
Internal Medicine — Payments: $249,957
Internal Medicine $249,957
Dr. Patrick Hu, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $156,562
Internal Medicine $156,562
Dr. Edward Kim, M.d, M.D
Internal Medicine — Payments: $66,215
Internal Medicine $66,215
Sarah Lavery, Md, MD
Internal Medicine — Payments: $47,404
Internal Medicine $47,404
Michael Stein, M.d, M.D
Internal Medicine — Payments: $19,000
Internal Medicine $19,000
Nikhil Ghatnekar, Do, Mba, DO, MBA
Internal Medicine — Payments: $16,284
Internal Medicine $16,284